A new report from Wedbush focuses on upcoming catalysts for biotech stocks in the firm's coverage universe. These four have monster potential upside to the posted price targets.
According to one analyst, Advaxis shares could still easily more than double, even after news broke that biotech giant Amgen will become its partner.
The presence of the Zika virus is not concentrated in Florida, although the state has more confirmed cases than any other, and the number of infected people is growing rapidly.
When Pfizer reported its second-quarter financial results before the markets opened on Tuesday, investors initially did not appear impressed.
On Monday, the CDC issued its first-ever travel warning for a destination inside the United States. The warning could pose a threat to Florida's tourism industry.
The upcoming earnings report will showcase what Pfizer has to offer for the second half of 2016, and potentially give some insight into what companies it may be looking to pursue next.
ThinkstockShares of Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) sank on Monday after the company announced that there will be an interruption in the supply of Auryxia (ferric citrate) tablets due to a production-related issue converting active…
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Shares of Biogen and, especially, Ionis Pharmaceuticals made handy gains early Monday morning following favorable interim results from a late-stage trial.
Gilead Sciences reported its earnings on Monday of last week, and since that time there has been much analyst activity around the stock.
When Boston Scientific reported second-quarter results Wednesday, revenues were up 10% overall, with medical and surgical product sales up nearly 30%.
These three biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the last year and are offering aggressive accounts the best entry points in…
The recent performance from Gilead Sciences has analysts and investors concerned about the future. Argus believes that the headwinds are blowing harder than the tailwinds for the company.
Shares of Seres Therapeutics took an absolute dive early in Friday’s session as the company stared down the barrel of a seemingly failed mid-stage clinical trial.
AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
